This Biotech Rags-to-Riches Story Could Deliver Blockbuster ProfitsBy William Patalon III, Executive Editor, Money Morning • September 8, 2016Start the conversationLeave a Reply Click here to cancel reply.Your email address will not be published. Required fields are marked *Name * Email * Website + three = six Comment Some HTML is OK Sign me up for the Money Morning newsletter William Patalon IIIWe love a good comeback story.Especially when it involves a developmental-stage biotech firm...Earlier this year, Trevena Inc. (Nasdaq: TRVN), a clinical-stage biopharmaceutical company received a double dose of bad news for its acute heart failure drug, TRV027, after it failed to meet either of its target outcomes (known as primary and secondary "endpoints" in drug-study jargon).That news sent its stock down 18% for the day.This is premium content for Private Briefing subscribers only. As the executive editor of Money Morning, Bill Patalon has perfected a secret investment strategy that could help you put an extra $125K into your portfolio - this year. To date, Bill has used this strategy to pick 257 winning investments, including 192 double- and triple-digit peak gains. Once you see the secret, you'll immediately understand why it works so well.